As I see it

Share this article:
“Newspeak,” as Orwellian cognoscenti know, is the official language of Big Brother, designed “not to extend but to diminish the range of thought.” Its goal was to “make all other modes of thought impossible.”  
Which brings us from the nightmare fantasy of 1984 to the healthcare debate of 2011 and the concept of “cost-think.” And nowhere is cost-think more crucial than when it comes to publicly bankrolled dissemination of tax-payer funded and government-fielded comparative effectiveness research.
There are many important questions yet unanswered. Will these studies be peer-reviewed before release? To whom will they be communicated—and how? Will physicians be “academically detailed?” Will physicians be given incentives to spend time with Uncle Sam's comparative effectiveness angels and punished if they do not? How will Uncle Sam decide which doctors are to be visited? Will “high prescribers” of on-patent medicines be on a priority list, identified by mechanisms being developed to enforce states' physician sunshine laws?
What kind of safe guards will be in place to certify physicians are presented with information that is unbiased? And who will define what “unbiased” means? Previous government studies (CATIE, ALLHAT) have focused on short-term cost savings vs. a more patient-centric approach treatment.
 Who will decide what these detailers can say? Will government “reps” have to play by the same rules as their pharma counterparts?
“Words,” said Rudyard Kipling, “are the most powerful drug used by mankind.” We allow them to be usurped and corrupted at our own peril.
Peter Pitts is senior partner/director of global regulatory & health policy at Porter Novelli and a former FDA associate commissioner
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications